Send us Fan Mail

What if medicines could actually “decide” when and where to activate inside the body? MIT-trained synthetic biologist Dr. Jacob Becraft, Ph.D. is building programmable therapies that behave less like traditional drugs…and more like biological software.

Dr. Becraft is Co-Founder and CEO of Strand Therapeutics ( https://www.strandtx.com/ ), a company pioneering what may become one of the next great frontiers in medicine: programmable mRNA therapeutics.

Long before mRNA became a household term through COVID vaccines, Dr. Becraft and his colleagues at MIT were developing what has been described as the world’s first synthetic biology programming language for mRNA - technology designed not simply to deliver genetic instructions, but to create logic-driven therapies capable of making decisions inside living cells.

Now Strand is translating that vision into cancer therapeutics, with early clinical data from its lead candidate STX-001 showing responses in patients with advanced solid tumors who had exhausted conventional options - including evidence of systemic immune activity and even complete responses.

Beyond the science, Jake is also a leading voice in synthetic biology, biotech entrepreneurship, and the future relationship between software, biology, and medicine.

#StrandTherapeutics #JacobBecraft #SyntheticBiology #mRNA #ProgrammableMedicine #CancerImmunotherapy #Immunotherapy #Biotech #PrecisionMedicine #GeneTherapy #SyntheticBiologyEngineering #FutureOfMedicine #Oncology #CAR_T #mRNATherapeutics #Bioengineering #IL12 #RNA #MIT #CellTherapy #Longevity #Biotechnology #MedicalInnovation #NextGenMedicine #CancerResearch #AIinBiology #HealthcareInnovation #GeneticMedicine #ScientificBreakthrough #ProgressPotentialPossibilities

Support the show